On March 30, 2023 — AlphaPrime Life Sciences Group (hereinafter referred to as "AlphaPrime"), announced its collaboration with CSPC Pharmaceutical Group Co., Ltd (referred to as "CSPC"), one of China's leading innovative pharmaceutical companies, to officially launch the AuroraPrime Create (referred to as "Prime Create"), an intelligent clinical research document generation system. CSPC will fully utilize the system to write clinical research protocols and CSR (clinical study reports) to improve content writing, cross-team collaboration, and approval process efficiency, achieve digitization and structuring of document content, establish an enterprise-level content knowledge base, and realize comprehensive knowledge accumulation and application for innovative research and development.

On March 30, 2023 — AlphaLife Sciences Group (hereinafter referred to as "AlphaLife"), announced its collaboration with CSPC Pharmaceutical Group Co., Ltd (referred to as "CSPC"), one of China's leading innovative pharmaceutical companies, to officially launch the AuroraPrime Create (referred to as "Prime Create"), an intelligent clinical research document generation system. CSPC will fully utilize the system to write clinical research protocols and CSR (clinical study reports) to improve content writing, cross-team collaboration, and approval process efficiency, achieve digitization and structuring of document content, establish an enterprise-level content knowledge base, and realize comprehensive knowledge accumulation and application for innovative research and development.

Clinical Department of CSPC:

"CSPC is committed to the development of innovative drugs and operates a large number of clinical trial projects every year, with a rigorous scientific attitude to explore the safety and efficacy of investigational drugs. From the design and writing of the clinical trial protocol at the beginning to the generation of the CSR at the end, the quality of the content and the efficiency of content production are important to us. The value of knowledge and experience from a large amount of existing document content can only be provided by an enterprise-level system. We hope to use computer technology such as machine learning to quickly improve the knowledge accumulation of trial document content and create a complete and structured knowledge base, realizing the integration and application of content and data in the intelligent system, and ultimately empowering CSPC's efficient and intelligent process in the clinical development of new drugs."

Medical Writing and Information Department of CSPC:

"In our daily work as the medical writing team of CSPC in the past, we needed to complete a large number of trial protocols and CSR through collaborative communication. After the content was completed, it also needed to undergo rigorous review and approval. These tasks were completed through traditional communication channels, which was time-consuming. On the other hand, it also required considerable manpower and time costs to refer to and learn from the final draft documents. Therefore, we considered whether an enterprise-level system solution could be adopted to optimize the entire process and whether artificial intelligence-related technologies could be applied to professional medical writing scenarios. Ideally, this system needs to have content writing assistance and even the ability to generate content intelligently, while also realizing structured content, online team collaboration, historical version management, approval flow, knowledge retention, and application of many details, professional, and convenient functions. We are pleased to finally collaborate with AlphaLife and see the system capabilities we expected in the Prime Create, as well as more intelligent expansion and future possibilities."

Ms. Xiao Chen, CEO of AlphaLife Sciences:

"We are honored to provide globally leading technology and product support for the informationization of clinical research at CSPC. AlphaLife has built a stable, integrated, open, and intelligent clinical research platform, AuroraPrime, starting from the writing of trial protocols, in which Prime Create is a professional system for clinical research document writing scenarios. It realizes cross-team, cross-department, and cross-organization collaborative editing, approval flow that can conform to enterprise compliance standards, rich and conforming content templates based on the enterprise's document knowledge base and public database, intelligent recognition and processing, and recommendation of appropriate reference content during the writing process to improve writing efficiency. Prime Create structurizes and standardizes the overall content of documents, making it a usable data flow, enabling the AuroraPrime's Clinical Logic Engine to understand and extract value from document content, which is one of the important empowering scenarios for AlphaLife's intelligent clinical research system solution."

About CSPC:

CSPC Pharmaceutical Group Limited ("CSPC") (Stock code: 1093.HK) is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994 and became a constituent stock of the Hang Sang Index in 2018 (the 1st constituent stock in the pharmaceutical sector since launch of the index). CSPC is currently also a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng SCHK Mainland China Healthcare Index", "Hang Seng Stock Connect Hong Kong Index", "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index".

About AlphaLife Sciences：

AlphaLife Sciences is focused on the clinical research and development field of life sciences, and is committed to creating a globally leading new generation of clinical research SaaS platform. It leverages cloud computing, big data, AI, and other technologies to empower the trial design, data management, and operation of life science research and development, ensuring clinical data consistency, improving design and execution efficiency, controlling cost input, accelerating the commercialization of innovative drugs and new medical devices, and benefiting human health.